- Home
- VMEO vs XERS Comparison
VMEO vs XERS Comparison
Compare VMEO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- XERS
- Stock Information
- Founded
- VMEO 2004
- XERS 2005
- Country
- VMEO United States
- XERS United States
- Employees
- VMEO N/A
- XERS N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- XERS Health Care
- Exchange
- VMEO Nasdaq
- XERS Nasdaq
- Market Cap
- VMEO 751.2M
- XERS 628.7M
- IPO Year
- VMEO N/A
- XERS 2018
- Fundamental
- Price
- VMEO $4.40
- XERS $4.95
- Analyst Decision
- VMEO Buy
- XERS Strong Buy
- Analyst Count
- VMEO 4
- XERS 6
- Target Price
- VMEO $7.35
- XERS $6.25
- AVG Volume (30 Days)
- VMEO 1.3M
- XERS 2.2M
- Earning Date
- VMEO 05-05-2025
- XERS 05-08-2025
- Dividend Yield
- VMEO N/A
- XERS N/A
- EPS Growth
- VMEO N/A
- XERS N/A
- EPS
- VMEO 0.10
- XERS N/A
- Revenue
- VMEO $415,130,000.00
- XERS $222,551,000.00
- Revenue This Year
- VMEO $3.90
- XERS $33.96
- Revenue Next Year
- VMEO $6.17
- XERS $19.87
- P/E Ratio
- VMEO $42.77
- XERS N/A
- Revenue Growth
- VMEO N/A
- XERS 29.88
- 52 Week Low
- VMEO $3.45
- XERS $1.96
- 52 Week High
- VMEO $7.90
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- VMEO 32.35
- XERS 54.35
- Support Level
- VMEO $4.35
- XERS $4.71
- Resistance Level
- VMEO $4.52
- XERS $5.09
- Average True Range (ATR)
- VMEO 0.11
- XERS 0.22
- MACD
- VMEO -0.02
- XERS -0.00
- Stochastic Oscillator
- VMEO 0.00
- XERS 58.93
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. The comprehensive and cloud-based tools of the company empower its users to create, share, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).